.jpg/jcr:content.webp)
Vaccines
Science in Vaccines
Beyfortus®: Made with All Infants in Mind to Protect Against RSV
Up to 75% of RSV-associated hospitalisations occur in healthy and full-term children.2 Recent studies have shown that nirsevimab provided up to 90% protection against hospitalisation from severe RSV LRTI in infants during their first RSV season.3
RSV Prevention for Every Infant: Favourable Safety Profile
RSV is the primary cause of LRTIs in children worldwide.2 Infants aged 3 months old have the highest risk of severe RSV LRTIs.2
Understanding RSV: Disease Burden and Nirsevimab’s Efficacy
In Singapore, RSV circulates all-year round and causes significant paediatric health and economic burden.2 This highlights the need and importance of RSV immunisation to reduce the burden of disease.2
Please log in or register to continue reading.
Request-form
